✦ LIBER ✦

High-dose chronomodulated infusion of 5-fluorouracil (5-FU) and folinic acid (FA) (FF5–16) in advanced colorectal cancer patients

✍ Scribed by Edmondo Terzoli; Carlo Garufi; Albina Rita Zappalà; Barbara Vanni; Patrizia Pugliese; Giancarlo Antonini Cappellini; Anna Maria Aschelter; Maria Perrone; Diana Giannarelli

Publisher: Springer-Verlag
Year: 2004
Tongue: English
Weight: 217 KB
Volume: 130
Category: Article
ISSN: 1432-1335
DOI: 10.1007/s00432-004-0560-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High dose folinic acid and 5-fluorouraci

High dose folinic acid and 5-fluorouracil bolus and continuous infusion for patients with advanced colorectal cancer

✍ Yves H. Bécouarn; René C. Brunet; Marie-Laurence P. Rouhier; Emmanuel J. Bussièr 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 530 KB

Randomized phase III Study of 5-fluorour

Randomized phase III Study of 5-fluorouracil plus high dose folinic acid versus 5-fluorouracil plus folinic acid plus methyl-lomustine for patients with advanced colorectal cancer

✍ Dennie V. Jones; Roger J. Winn; Barry W. Brown; Lawrence B. Levy; Reginald P. Pu 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 501 KB

Background. Metastatic colorectal cancer is generally incurable. The most active regimen available, 5-fluorouracil(5-FU) and folinic acid (Leucovorin), produces response rates of approximately 25% to 30%. Methyl-lomustine is a nitrosourea with modest activity against colorectal cancer. A randomized

Irinotecan and chronomodulated infusion

Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma : A Phase I study

✍ Carlo Garufi; Luigi Dogliotti; Rita M. D'Attino; Marco Tampellini; Anna M. Asche 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 3 views

Relationship between 5-fluorouracil (5-F

Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU

✍ Erick C. Gamelin; Etienne M. Danquechin-Dorval; Yvan F. Dumesnil; Philippe J. Ma 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 977 KB

## BACKGROUND. A phase I1 prospective trial was carried out to study the concept of 5-fluorouracil (5-FU) dose-intensity in patients with advanced colorectal cancer. Forty patients were treated with 5-FU plus leucovorin (LV), with individually increasing doses of 5-FU. A 5-FU pharmacokinetic follo

Bimonthly high dose leucovorin and 5-flu

Bimonthly high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in patients with advanced colorectal carcinoma

✍ Karine Beerblock; Yves Rinaldi; Thierry André; Christophe Louvet; Eric Raymond; 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 2 views

with low dose LV. Based on these reports, a first-line Phase II study was performed in 101 patients with advanced colorectal carcinoma who were given a bimonthly

A phase II trial of weekly high dose con

A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer

✍ Enrique Aranda; Andrés Cervantes; Javier Dorta; Esperanza Blanco; Carlos Fernánd 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 419 KB 👁 2 views

Background. In a previous Phase I1 trial, the authors showed that a weekly continuous infusion of 5-fluorouracil (5-FU) at a dose of 3.5 g/mz for 48 hours is an active treatment for advanced colorectal cancer. The overall response rate was 38.5%, and the median survival was 12 months. These data wer